A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/11/2004	WO2004096950A1 Antioxidative composition
11/11/2004	WO2004096862A2 Improved extration and purification method for cereal beta (1-3) beta (1-4) glucan
11/11/2004	WO2004096829A2 Novel method and intermediates for the preparation of 19-nor-steroids-17-halogen compounds
11/11/2004	WO2004096828A2 Novel method and intermediates for the preparation of 19-nor-steroid compounds
11/11/2004	WO2004096823A2 Novel ketolide derivatives
11/11/2004	WO2004096820A1 Tumor selective and biodegradable polyphosphazene-platinum(ii) conjugate antitumor agent, and preparation method thereof
11/11/2004	WO2004096818A2 Method and compositions for identifying anti-hiv therapeutic compounds
11/11/2004	WO2004096808A1 Triazine compounds and their use
11/11/2004	WO2004096806A1 Fused imidazole derivative
11/11/2004	WO2004096803A1 Azabicyclononene derivatives
11/11/2004	WO2004096802A2 ANTIBIOTIC TETRAHYDRO-β-CARBOLINE DERIVATIVES
11/11/2004	WO2004096801A1 Cannabinoid receptor ligands and uses thereof
11/11/2004	WO2004096795A2 C-fms kinase inhibitors
11/11/2004	WO2004096784A1 New heterocyclic amides exhibiting an inhibitory activity at the vanilloid receptor 1 (vr1).
11/11/2004	WO2004096748A1 Preparation method of conjugated linoleic acid diglycerides
11/11/2004	WO2004096367A1 A wound-cover material containing radical scavengers
11/11/2004	WO2004096366A1 9-azabicyclo’3.3.1!non-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
11/11/2004	WO2004096287A2 Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
11/11/2004	WO2004096286A2 Antiviral phosphonate analogs
11/11/2004	WO2004096285A2 Anti-infective phosphonate conjugates
11/11/2004	WO2004096281A1 Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof
11/11/2004	WO2004096280A1 Composition containing medicine extremely slightly soluble in water and method for preparation thereof
11/11/2004	WO2004096279A1 Composition for injection
11/11/2004	WO2004096278A1 Adiponectin production enhancer
11/11/2004	WO2004096276A1 Sugar intake-ability enhancer
11/11/2004	WO2004096274A1 Drug for airway administration
11/11/2004	WO2004096273A1 Methods for treating interleukin-6 related diseases
11/11/2004	WO2004096265A1 Nutrient liquid containing human growth hormone and the preparation method thereof
11/11/2004	WO2004096260A1 Preventives or remedies for hepatopathy
11/11/2004	WO2004096259A1 Methods and compositions using gonadotropin hormone releasing hormone
11/11/2004	WO2004096256A1 Methods for preventing and treating loss of balance function due to oxidative stress
11/11/2004	WO2004096254A2 Transferrin conjugates for tumor treatment
11/11/2004	WO2004096253A1 Use of inhibitors and antisense oligonucleotides of btk for treating proliferative mastocytosis
11/11/2004	WO2004096243A1 Agent for preventing and ameliorating constipation
11/11/2004	WO2004096242A1 Pharmaceutical compositions comprising cereal beta (1-3) beta (1-4) glucan
11/11/2004	WO2004096241A1 Hmpv treatment with ribavirin and anti-hmpv antibody
11/11/2004	WO2004096240A1 Anthocyanins useful for the treatment of diabetes, cardiovascular disorders and to lower the risk of adverse effects of hormone replacement therapy
11/11/2004	WO2004096239A1 Method for administration of troxacitabine
11/11/2004	WO2004096238A1 Nucleic acid compositions and methods for use
11/11/2004	WO2004096237A2 Phosphonate analogs for treating metabolic diseases
11/11/2004	WO2004096236A2 Immunomodulator phosphonate conjugates
11/11/2004	WO2004096235A2 Anti-cancer phosphonate analogs
11/11/2004	WO2004096234A2 Kinase inhibitor phosphonate conjugates
11/11/2004	WO2004096233A2 Nucleoside phosphonate conjugates
11/11/2004	WO2004096232A1 Interleukin-8 enhancer
11/11/2004	WO2004096231A2 Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
11/11/2004	WO2004096230A1 Remedy for rheumatoid arthritis
11/11/2004	WO2004096229A1 Medicinal composition in solution form
11/11/2004	WO2004096228A1 Method of improved diuresis in individuals with impaired renal function
11/11/2004	WO2004096225A2 Use of tyrosine kinase inhibitors for treating cerebral ischemia
11/11/2004	WO2004096224A2 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
11/11/2004	WO2004096223A1 Use of irinotecan for treatment of resistant breast cancer
11/11/2004	WO2004096222A1 Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders
11/11/2004	WO2004096221A1 Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
11/11/2004	WO2004096219A1 Prophylactic pretreatment with antioxidants
11/11/2004	WO2004096218A2 Pellet formulations of acid-labile antiulcer benzimidazole compounds
11/11/2004	WO2004096217A1 Use of n-type calcium channel inhibitors in treating demyelinating diseases
11/11/2004	WO2004096216A2 Use of a topical medicament comprising riluzole
11/11/2004	WO2004096215A1 Pharmaceutical formulation of the sodium salt of telmisartan
11/11/2004	WO2004096214A1 A rapidly disintegrable composition for masking the bitter taste of ondansetron or a pharmaceutically acceptable salt thereof
11/11/2004	WO2004096211A1 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes
11/11/2004	WO2004096209A1 The use of azetidinecarboxamide derivatives in therapy
11/11/2004	WO2004096208A1 Composition for oral administration containing alkylene dioxybenzene derivative
11/11/2004	WO2004096207A1 Body-temperature lowering depressant
11/11/2004	WO2004096206A2 Therapeutic combination of a cox-2 inhibitor and a tace inhibitor
11/11/2004	WO2004096205A1 A process for producing an additive comprising a salt obtained from hydroxy methionine and a trace element
11/11/2004	WO2004096204A1 Lactate containing pharmaceutical composition and uses thereof
11/11/2004	WO2004096203A1 Use of oleanolic acid as a vasodilator and restorer agent for endothelial dysfunction
11/11/2004	WO2004096202A1 Pharmaceutical formulation comprising anti-obesity agent and acidulant
11/11/2004	WO2004096201A1 Compositions for affecting weight loss
11/11/2004	WO2004096200A1 Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse
11/11/2004	WO2004096199A2 Regulation of guanine nucleotide exchange factor
11/11/2004	WO2004096198A1 Therapeutic agent
11/11/2004	WO2004096197A2 5-aza-7-deazapurine nucleosides for treating flaviviridae
11/11/2004	WO2004096196A2 Treatment of incontinence with 5htc2 agonists
11/11/2004	WO2004096195A2 Use of ppar-gamma agonists as anti-infective agents
11/11/2004	WO2004096194A2 Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains
11/11/2004	WO2004096192A1 Fast dissolving orally consumable films containing a sucralose as a sweetener
11/11/2004	WO2004096191A1 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances
11/11/2004	WO2004096189A2 The dispersible alendronate microparticle formulation
11/11/2004	WO2004096187A1 Pharmaceutical composition containing ribavirin as active substance and method of manufacturing thereof
11/11/2004	WO2004096186A1 Extended release venlafaxine tablet formulation
11/11/2004	WO2004096183A1 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
11/11/2004	WO2004096182A1 Extended release matrix tablets of carvedilol
11/11/2004	WO2004096180A1 Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
11/11/2004	WO2004096174A1 Fast dissolving orally consumable films containing pharmaceutically active agents
11/11/2004	WO2004096158A2 Inhibiting viral infections
11/11/2004	WO2004096154A2 Methods for treating degenerative diseases/injuries
11/11/2004	WO2004096151A2 Methods and devices for the sustained release of multiple drugs
11/11/2004	WO2004096147A2 Oxo-pyrimidine compounds
11/11/2004	WO2004096146A2 Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
11/11/2004	WO2004096144A2 Compositions and methods for induction of opioid receptors
11/11/2004	WO2004096143A2 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility
11/11/2004	WO2004096141A2 Method for promoting uninterrupted sleep by administration of trospium chloride
11/11/2004	WO2004096139A2 Aza spiro alkane derivatives as inhibitors of metalloproteases
11/11/2004	WO2004096138A2 [18f]-furanosylpurine derivatives and uses thereof
11/11/2004	WO2004096137A2 Annatto extract compositions, including geranyl geraniols and methods of use
11/11/2004	WO2004096136A2 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
11/11/2004	WO2004096135A2 Inhibitors of akt activity
11/11/2004	WO2004096131A2 Inhibitors of akt activity

1 ... 4893 4894 4895 4896 4897 4898 4899 4900 4901 4902 4903 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 ... 7860